Speech impairment in Parkinson's disease is improved by trancranial application of electromagnetic fields

International Journal of Neuroscience

Volumn 92, Issue 1-2, 1997, Pages 63-72

  Sandyk, Reuven ^a,b  

^a TOURO COLLEGE   (United States)

^b NONE   (United States)

Author keywords

Electromagnetic fields; Parkinson's disease; Serotonin; Sertraline; Speech impairment; Stuttering

Indexed keywords

EID: 0031278014     PISSN: 00207454     EISSN: None     Source Type: Journal    
DOI: 10.3109/00207459708986390     Document Type: Article

References (59)

1. Adell, A., Trullas, R. & Gelpi, I. (1988). Time course of changes in serotonin and noradrenaline in rat brain after predictable or unpredictable shock. Brain Research, 459, 54-59.
2. Artigas, F., Perez, V. & Alvarez, E. (1994). Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Archives of General Psychiatry, 51, 248-251.
3. Bawin, S. M. & Adey, W. R. (1976). Sensitivity of calcium binding in cerebral tissue to weak environmental electric fields oscillating at low frequency. Proceedings of the National Academy of Sciences, USA, 73, 1999-2003.
4. Biary, N., Pimental, P. & Langenberg, P. W. (1988). A double blind trial of clonazepam in the treatment of parkinsonian dysarthria. Neurology, 38, 255-258.
5. Birkmayer, W & Riederer, P. (1980). Die Parkinson Krankheit. Biochemie, Klinik, Therapie. (Springer Verlag: Wien.)
6. Brady, J. P. (1991). The pharmacology of stuttering. a critical review. American Journal of Psychiatry, 148, 1309-1316.
7. Brunello, N., Barabaccia, M. L., Chuang, D. M. & Costa, E. (1982). Down-regulation of beta-adrenergic receptors following repeated injections of desmethylimipramine. Permissive role of serotonergic neurons. Neuropharmacoogy, 21, 1145-1149.
8. Comings, D. E. (1990). Tourette syndrome and human behavior, pp. 18 & 345, (Hope Press, Duarte, CA.)
9. Comings, D. E & Comings, B. E. (1987). A controlled study of Tourette syndrome. American Journal of Human Genetics, 41, 701-741.
10. Costall, B., Naylor, R. J., Marsden, C & Pycock, C. J. (1976). Serotonergic modulation of the dopamine responses from the nucleus accumbens Journal of Pharmacy and Pharmacology, 28, 523-526.
11. Critchley, E. M. R. (1981). Speech disorders of parkinsonism: a review. Journal of Neurology Neurosurgery and Psychiatry, 44, 751-758.
12. Darley, F. L., Aronson, A E. & Brown, J. R. (1975) Motor speech disorders, pp. 171-197 (W.B. Saunders, Philadelphia.)
13. Davidson, D. L. W., Yates, C. M., Yates, C. M., Mawdsley, C., Pullar, I. A. & Wilson, H. (1977). CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders. Journal of Neurology Neurosurgery and Psychiatry, 40, 1136-1141.
14. Dray, A. (1981). Serotonin in the basal ganglia: functions and interactions with other neuronal pathways. Journal of Physiology, (Paris), 77, 393-403.
15. Durif, F., Vidailhet, M., Bonnet, A. M., Blin, J. & Agid, Y. (1995). Levodopa-induced dyskinesias are improved by fluoxetine. Neurology, 45, 1855-1858.
16. Everett, G. M. & Borcherding, J. W. (1970). L-dopa: effect on concentration of dopamine, norepinephrine, and serotonin in brains of mice. Science, 168, 849-850.
17. Fahn, S., Libsch, L. R & Cutler, R. W. (1971). Monoamines in the human neostriatum: Topographic distribution in normals in Parkinson's disease and their role in akinesia, rigidity, chorea and tremor. Journal of Neurological Sciences, 14, 427-455.
18. Fontenot, M. B., Kaplan, J. R., Manuck, S. B., Arango, V. & Mann, J. J. (1995). Long-term effects of chronic social stress on serotonergic indices in the prefrontal cortex of adult male cynomolgus macaques. Brain Research, 705, 105-108.
19. Fuller, R. W. (1986). Pharmacologic modification of serotonergic function: drugs for the study and treatment of psychiatric and other disorders Journal of Clinical Psychiatry, 47 (suppl 4), 4-8.
20. Gershanik, O. S., Heikkila, R. E. & Duvoisin, R. C. (1979). The role of serotonin neurons in the action of L-dopa in an animal model of Parkinsonism. Neurology, 29, 553.
21. Goldstein, J. A. (1987). Carbamazepine treatment for stuttering. Journal of Clinical Psychiatry, 48, 39.
22. Hesselink, J. M. K. (1993). Serotonin, depression and PD. Neurology, 43, 1624-1625.
23. Hoehn, M. M. & Yahr, M. D. (1967). Parkinsonism: onset, progression, and mortality. Neurology, 17, 427-442.
24. Hwang, E. C. & Van Woert, M. H. (1979). Antimyoclnic action of clonazepam: the role of serotonin. European Journal of Pharmacology, 60, 31-40.
25. Jaffe, R. A., Laszewski, B. L., Carr, D B & Phillips, R. D. (1980). Chronic exposure to a 60-Hz electric field: effects on synaptic transmission and peripheral nerve function in the rat. Bioelectromagnetics, 1, 131-147.
26. Javoy-Agid, F., Ruberg, M., Taquet, H., Bokobza, B., Agid, Y., Gaspar, P , Berger, B., N'Guyen-Legros, J., Alvarez, C., Gray, F., Escourolle, R., Scatton, B. & Rouquier, L. (1984). Biochemical neuropathology of Parkinson's disease. In R.G. Hassler & J.F. Christ (Eds.), Advances in neurology, vol. 40, pp. 189-198. (Raven Press, New York.)
27. Jurgens, U. & Ploog, D. (1981). On the neural control of mammalian vocalization. Trends in Neurosciences, 4, 135-137.
28. Kienzl, E., Riederer, P., Jellinger, K. & Wesemann, W. (1981). Transitional states of centreal serotonin receptors in Parkinson's disease. Journal of Neural Transmission, 51, 113-122.
29. Kiziltan, G & Akalin, M. A. (1996). Stuttering may be a type of action dystonia. Movement Disorders, 11, 278-282.
30. Koller, W. C. (1983). Dysfluency (stuttering) in extrapyramidal disease. Archives of Neurology, 40, 175-177.
31. Kostic, V. S., Dijuric, B. M , Covickovic-Stemic, N., Bumbasirevic, L., Nicolic, M. & Mrsulja, B. B. (1987). Depression and Parkinson's disease: possible role of serotonergic mechanisms. Journal of Neurology, 234, 94-96.
32. Logemann, J. A., Fisher, H. B., Boshes, B. & Blonsky, E. R. (1978). Frequency and occurrence of vocal tract dysfunction in the speech of a large sample of Parkinson patients. Journal of Speech & Hearing Disorders, 43, 47-57.
33. Markstein, R. (1981). Neurochemical effects of some ergot derivatives: a basis for their antiparkinsonian actions. Journal of Neural Transmission, 51, 39-59.
34. Marsden, C. D. & Parkes, J. D. (1980). "On and off" variability and response swings in Parkinson's disease. In F.C Rose & R. Capildeo (eds.), Research progress in parkinson's disease, pp. 265-274, (Pitman Medical, Kent.)
35. Mayeux, R., Stern, Y., Sano, M., Cote, L. & Williams, J B. W. (1987). Clinical and biochemical correlates of bradyphrenia in Parkinson's disease. Neurology, 37, 1130-1134.
36. Mayeux, R., Stern, Y., Williams, J. B. W. & Cote, L. J. (1988). The relationship of serotonin to depression in Parkinson's disease. Movement Disorders, 3, 237-244.
37. McCance-Katz, E. F., Marek, K. L & Price, L. H. (1992). Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology, 42, 1813-1814.
38. Meara, J. (1996). Serotonin and the extrapyramidal system- a neurological perspective. Human Psychopharmacology, 11, S95-S102.
39. Mlcoch, A. G. (1987). Diagnosis and treatment of parkinsonian dysarthria. In Koller, W.C. (Ed.), Handbook of Parkinson's disease, pp. 181-207. (Marcel Dekker, Inc., New York)
40. Nieuwenhuys, R. (1985). Chemoarchitecture of the brain, pp. 33-41. (Springer Verlag, Berlin.)
41. Pujol, J. F. (1979). Interactions between serotonin and noradrenaline containing neurons: link between the raphe system and the locus coeruleus. In P. Simon (ed.), Advances in pharmacological therapeutics, vol. 2, pp. 417-429. (Pergamon Press, Oxford.)
42. Riederer, P. (1980). L-dopa competes with tyrosine and tryptophan for human brain uptake. Nutrition & Metabolism, 24, 417-423.
43. Sandyk, R. (1992 a). Weak magnetic fields as a novel therapeutic modality in Parkinson's disease. International Journal of Neuroscience, 66, 1-15
44. Sandyk, R. (1992 b). Weak magnetic fields in the treatment of Parkinson's disease with the "on-off" phenomenon. International Journal of Neuroscience, 66, 97-106.
45. Sandyk, R. (1992 c). Magnetic fields in the therapy of Parkinsonism. International Journal of Neuroscience, 66, 209-235.
46. Sandyk, R. (1994 a). A drug naive Parkinsonian patient successfully treated with electromagnetic fields. International Journal of Neuroscience, 79, 99-110.
47. Sandyk, R. (1994 b). Treatment of Parkinson's disease with magnetic fields reduces the requirement for antiparkinsonian medications. International Journal of Neuroscience, 74, 191-201.
48. Sandyk, R. (1996). Freezing of gait in Parkinson's disease is improved by treatment with weak electromagnetic fields. International Journal of Neuroscience, 85, 111-124
49. Sandyk, R. Treatment with AC pulsed electromagnetic fields improves the response to levodopa in Parkinson's disease. International Journal of Neuroscience, (in press).
50. Sandyk, R. & Derpapas, K. (1993). Further observations on the unique efficacy of picotesla magnetic fields in Parkinson's disease. International Journal of Neuroscience, 69, 167-183.
51. Sandyk, R. & Iacono, R. P. (1993). Reversal of visual neglect in Parkinson's disease by treatment with picotesla range magnetic fields. International Journal of Neuroscience, 73, 93-107
52. Sandyk, R. & Fisher, H. (1988). Serotonin in involuntary movement disorders. International Journal of Neuroscience, 42, 185-205.
53. Sandyk, R. & Fisher, H. (1989). L-tryptophan supplementation in Parkinson's disease. International Journal of Neuroscience, 45, 215-219.
54. Sawada, M., Nagatsu, T., Nagtsu, I., Ito, K., Iizuka, R., Kondo, T & Narabayashi, H. (1985). Tryptophan hydroxylase activity in the brains of controls and Parkinsonian patients. Journal of Neural Transmission, 62, 107-115
55. Scatton, B., Javoy-Agid, F., Rouquier, L., Dubois, B. & Agid, Y. (1983). Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Research, 275, 321-328.
56. Scatton, B., Dennis, T., L'heureux, R., Monfort, J. C., Duyckaerts, C. & Javoy-Agid, F. (1986). Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients. Brain Research, 380, 181-185
57. Tetrud, J. W. (1991). Preclinical Parkinson's disease: detection of motor and nonmotor manifestations. Neurology, 41 (suppl 2), 69-72
58. Tohgi, H., Abe, T , Takahashi, S., Takahashi, J. & Hamato, H. (1993). Alteration in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration. Neuroscience Letters, 159, 135-138.
59. Wingate, M. E (1964). A standard definition of stuttering. Journal of Speech and Hearing Disorders, 29, 484-489.